# 2026-08122: FDA Seeks Input on Next COVID Vaccine Recipe for 2026

2026-08122, Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-United States (U.S.) 2026-2027 Formula for COVID-19 Vaccine Composition, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-27, effective 2026-05-28; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-08122
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08122
- Title: Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-United States (U.S.) 2026-2027 Formula for COVID-19 Vaccine Composition
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 22542
- Published: 2026-04-27
- Effective: 2026-05-28
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Seeks Input on Next COVID Vaccine Recipe for 2026

## Summary

The FDA is holding a public meeting on May 28, 2026, to decide the 2026-2027 formula for the COVID-19 vaccine. This affects everyone who gets vaccinated, as the vaccine’s ingredients might change to better fight the virus. The FDA wants your thoughts before May 27, 2026, so jump in and share your comments online—no cost, just your voice!

## Abstract

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

## Effects PRIA read

- FDA to Select 2026-2027 COVID Vaccine Formula: benefit, high. On May 28, 2026, the FDA advisory Committee will meet to discuss and make recommendations on the 2026-2027 formula for COVID-19 vaccines for use in the United States. This selection could change the vaccine ingredients used for people who get COVID-19 shots in the U.S.
- Public Comment Docket for Vaccine Formula: benefit, low. FDA opened a public docket (Docket No. FDA-2026-N-3962) for comments on the 2026-2027 COVID-19 vaccine formula. The docket closes May 27, 2026; comments submitted on or before May 21, 2026 will be provided to the Committee, and electronic comments are accepted until 11:59 p.m. ET on May 27, 2026.
- How to Make Oral Presentations to the Committee: benefit, low. Individuals may request to make formal oral presentations during the open public hearing (scheduled about 1:00–2:00 p.m. ET on May 28, 2026). Interested speakers must notify the contact person and submit a brief statement and contact details by 12 p.m. Eastern Time on May 18, 2026; the contact pers…
- Virtual Meeting Access and Disability Accommodations: benefit, low. The May 28, 2026 meeting will be conducted via online teleconference/video (with captions), streamed at the provided YouTube link, recorded, and FDA will provide disability accommodations if requested at least 7 days before the meeting. FDA waived certain in-person location requirements to allow th…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-08122 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/27/2026-08122/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-establishment-of-a)
- [2026-08122 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-27/pdf/2026-08122.pdf)

## Related
- [Previous: 2026-08121, Agency Information Collection Activities: Proposed New Information Collection A…](https://policyrisk.com/federal-register/2026-08121)
- [Next: 2026-08123, New Postal Products](https://policyrisk.com/federal-register/2026-08123)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08122 (as of 2026-06-08).
